NASDAQ: ILMN

Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum

Summary: 

New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health

Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability

Press Release

New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health

Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today

At ESMO 2022 in Paris, oncologists discussed real-world cases and big-picture challenges
Article

The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensiv

Illumina Grant Boosts Climate Action and Job Training

US nonprofit GRID Alternatives launches new projects to provide renewable energy
Article

As part of Illumina’s long-term commitment to sustainability, the Illumina Corporate Foundation made a one-year, $500,000 grant to support GRID Alternatives (Generating Renewable Ideas and Development Alternatives), a nonprofit committed to increasing access to renewable energy and training people for clean energy jobs.

Illumina Genomics Forum To Feature Diverse Lineup of Visionary Global Leaders

Full agenda now available for September 28–October 1 event
Press Release

SAN DIEGO, September 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum. The agenda for the four-day event can be seen here.

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

Presentations will include evidence on how genomic signatures and next-generation sequencing can improve the care of patients with cancer
Press Release

SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the upcoming presentation of multiple oncology research abstracts at this year’s European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina’s oncology assays for cancer research and patient care.

Delivering the Future of Diagnostics and Precision Oncology

At ECP 2022, Illumina presents new validation for TSO Comprehensive
Article

At the 34th European Congress of Pathology (ECP) in Basel, Switzerland, September 3 to 7, 2022, pathologists from more than 100 countries will convene to share and gain insights on advancements in their field. Illumina Director of Product Development Victor Sementchenko will deliver a presentation during the session, Molecular Pathology Diagnostics and Translational Research Symposium.

Illumina Genomics Forum To Feature Tennis Legend Chris Evert on the Role Genomics Played in Her Cancer Fight

Global conference to focus on advancing the life-saving impacts of genomic health care
Press Release

SAN DIEGO, September 2, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1. Evert, who was diagnosed with stage 1C ovarian cancer earlier this year, will participate in a fireside chat discussing how genomics can improve early cancer detection, lead to more proactive, effective treatment of cancer, and help save lives.

A New Kind of Liquid Biopsy

Canada’s STREAM project uses genomics to advance watershed health monitoring
Article

Rivers and streams are vital to communities everywhere, for drinking water, transportation, and leisure. But pollution, drought, and climate change are taking their toll, making watershed monitoring more important every year. That’s the urgency driving the recent Illumina philanthropic grantee Sequencing the Rivers for Environmental Assessment and Monitoring (STREAM), which samples freshwater rivers throughout Canada.

Minderoo Foundation and Illumina Commit $40M AUD To Apply Advanced Genomics to Marine Conservation

New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods
Press Release

SAN DIEGO, August. 17, 2022 /3BL Media/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will leverage the power of genomics to accelerate scientific understanding of marine systems and help marine conservationists make informed decisions. The three-year partnership demonstrates a shared commitment to conserving marine biodiversity and understanding the changing marine ecosystems on which people and national economies depend.

Illumina Genomics Forum To Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics

Session will showcase the rapidly growing use and groundbreaking impact of clinical genomics in oncology
Press Release

SAN DIEGO, August 24, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1. Dr. Knudsen will participate in an on-stage conversation with Dr. Phil Febbo, Illumina's Chief Medical Officer, about the landscape of cancer treatment and research, including what is currently being done to support the prevention, detection, and treatment of cancer.

Pages

Subscribe to NASDAQ: ILMN